AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feikin, D. R.
Right arrow Articles by Jorgensen, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feikin, D. R.
Right arrow Articles by Jorgensen, J. H.
Related Collections
Right arrow Immunization/Vaccines
Right arrow Other Infections
Right arrow Mortality

American Journal of Public Health, Vol 90, Issue 2 223-229, Copyright © 2000 by American Public Health Association

JOURNAL ARTICLE

Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997

DR Feikin, A Schuchat, M Kolczak, NL Barrett, LH Harrison, L Lefkowitz, A McGeer, MM Farley, DJ Vugia, C Lexau, KR Stefonek, JE Patterson and JH Jorgensen
Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Ga. 30333, USA.

OBJECTIVES: This study examined epidemiologic factors affecting mortality from pneumococcal pneumonia in 1995 through 1997. METHODS: Persons residing in a surveillance area who had community-acquired pneumonia requiring hospitalization and Streptococcus pneumoniae isolated from a sterile site were included in the analysis. Factors affecting mortality were evaluated in univariate and multivariate analyses. The number of deaths from pneumococcal pneumonia requiring hospitalization in the United States in 1996 was estimated. RESULTS: Of 5837 cases, 12% were fatal. Increased mortality was associated with older age, underlying disease. Asian race, and residence in Toronto/Peel, Ontario. When these factors were controlled for, increased mortality was not associated with resistance to penicillin or cefotaxime. However, when deaths during the first 4 hospital days were excluded, mortality was significantly associated with penicillin minimum inhibitory concentrations of 4.0 or higher and cefotaxime minimum inhibitory concentrations of 2.0 or higher. In 1996, about 7000 to 12,500 deaths occurred in the United States from pneumococcal pneumonia requiring hospitalization. CONCLUSIONS: Older age and underlying disease remain the most important factors influencing death from pneumococcal pneumonia. Mortality was not elevated in most infections with beta-lactam-resistant pneumococci.


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
A. P. MacGowan and on behalf of the BSAC Working Parties on Resistanc
Clinical implications of antimicrobial resistance for therapy
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii105 - ii114.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. B. Meropol
Valuing Reduced Antibiotic Use for Pediatric Acute Otitis Media
Pediatrics, April 1, 2008; 121(4): 669 - 673.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. Bordon, P. Peyrani, G. N. Brock, F. Blasi, J. Rello, T. File, J. Ramirez, and for the CAPO Study Group
The Presence of Pneumococcal Bacteremia Does Not Influence Clinical Outcomes in Patients With Community-Acquired Pneumonia: Results From the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study
Chest, March 1, 2008; 133(3): 618 - 624.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. J. Moore, A. M. Gilbey, C. G. Dowson, A. C. Pridmore, S. K. Dower, and R. C. Read
Proinflammatory activation of Toll-like receptor-2 during exposure of penicillin-resistant Streptococcus pneumoniae to {beta}-lactam antibiotics
J. Antimicrob. Chemother., January 1, 2007; 59(1): 35 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Abgueguen, E. Azoulay-Dupuis, V. Noel, P. Moine, V. Rieux, B. Fantin, and J.-P. Bedos
Amoxicillin Is Effective against Penicillin-Resistant Streptococcus pneumoniae Strains in a Mouse Pneumonia Model Simulating Human Pharmacokinetics
Antimicrob. Agents Chemother., January 1, 2007; 51(1): 208 - 214.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
R. Mangione-Smith, M. N. Elliott, T. Stivers, L. L. McDonald, and J. Heritage
Ruling out the need for antibiotics: are we sending the right message?
Arch Pediatr Adolesc Med, September 1, 2006; 160(9): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
B. Siquier, J. Sanchez-Alvarez, E. Garcia-Mendez, M. Sabria, J. Santos, R. Pallares, M. Twynholm, R. Dal-Re, and on behalf of the 620 Clinical Study Group
Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae
J. Antimicrob. Chemother., March 1, 2006; 57(3): 536 - 545.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. A. Lexau, R. Lynfield, R. Danila, T. Pilishvili, R. Facklam, M. M. Farley, L. H. Harrison, W. Schaffner, A. Reingold, N. M. Bennett, et al.
Changing Epidemiology of Invasive Pneumococcal Disease Among Older Adults in the Era of Pediatric Pneumococcal Conjugate Vaccine
JAMA, October 26, 2005; 294(16): 2043 - 2051.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. Weiss and G. S. Tillotson
The Controversy of Combination vs Monotherapy in the Treatment of Hospitalized Community-Acquired Pneumonia
Chest, August 1, 2005; 128(2): 940 - 946.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
N. Kasbekar and P. S. Acharya
Telithromycin: The first ketolide for the treatment of respiratory infections
Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Powis, A. McGeer, K. Green, O. Vanderkooi, K. Weiss, G. Zhanel, T. Mazzulli, M. Kuhn, D. Church, R. Davidson, et al.
In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3305 - 3311.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. M. File Jr., H. Lode, H. Kurz, R. Kozak, H. Xie, and E. Berkowitz
Double-Blind, Randomized Study of the Efficacy and Safety of Oral Pharmacokinetically Enhanced Amoxicillin-Clavulanate (2,000/125 Milligrams) versus Those of Amoxicillin-Clavulanate (875/125 Milligrams), Both Given Twice Daily for 7 Days, in Treatment of Bacterial Community-Acquired Pneumonia in Adults
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3323 - 3331.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. J. Schrag, L. McGee, C. G. Whitney, B. Beall, A. S. Craig, M. E. Choate, J. H. Jorgensen, R. R. Facklam, K. P. Klugman, and the Active Bacterial Core Surveillance Team
Emergence of Streptococcus pneumoniae with Very-High-Level Resistance to Penicillin
Antimicrob. Agents Chemother., August 1, 2004; 48(8): 3016 - 3023.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
V. Falco, B. Almirante, Q. Jordano, L. Calonge, O. del Valle, C. Pigrau, A. M. Planes, J. Gavalda, and A. Pahissa
Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?
J. Antimicrob. Chemother., August 1, 2004; 54(2): 481 - 488.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J.-H. Song, S.-I. Jung, K. S. Ko, N. Y. Kim, J. S. Son, H.-H. Chang, H. K. Ki, W. S. Oh, J. Y. Suh, K. R. Peck, et al.
High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study)
Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2101 - 2107.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. Croisier, M. Etienne, E. Bergoin, P.-E. Charles, C. Lequeu, L. Piroth, H. Portier, and P. Chavanet
Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy
Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1699 - 1707.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
J. Hamel, N. Charland, I. Pineau, C. Ouellet, S. Rioux, D. Martin, and B. R. Brodeur
Prevention of Pneumococcal Disease in Mice Immunized with Conserved Surface-Accessible Proteins
Infect. Immun., May 1, 2004; 72(5): 2659 - 2670.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
T. M. File Jr, J. Garau, F. Blasi, C. Chidiac, K. Klugman, H. Lode, J. R. Lonks, L. Mandell, J. Ramirez, and V. Yu
Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia
Chest, May 1, 2004; 125(5): 1888 - 1901.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
D. E. Low, M. E. Pichichero, and U. B. Schaad
Optimizing Antibacterial Therapy for Community-Acquired Respiratory Tract Infections in Children in an Era of Bacterial Resistance
Clinical Pediatrics, March 1, 2004; 43(2): 135 - 151.
[Abstract] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. H. Jorgensen, S. A. Crawford, M. L. McElmeel, and C. G. Whitney
Activities of Cethromycin and Telithromycin against Recent North American Isolates of Streptococcus pneumoniae
Antimicrob. Agents Chemother., February 1, 2004; 48(2): 605 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J.A. Preston, K.W. Beagley, P.G. Gibson, and P.M. Hansbro
Genetic background affects susceptibility in nonfatal pneumococcal bronchopneumonia
Eur. Respir. J., February 1, 2004; 23(2): 224 - 231.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. I. Restrepo, J. A. Velez, M. L. McElmeel, C. G. Whitney, and J. H. Jorgensen
Activity of Daptomycin against Recent North American Isolates of Streptococcus pneumoniae
Antimicrob. Agents Chemother., September 1, 2003; 47(9): 2974 - 2977.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. C. Dean
Encouraging News From the Antibiotic Resistance Front
Chest, August 1, 2003; 124(2): 423 - 424.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. E. Sisk, W. Whang, J. C. Butler, V.-P. Sneller, and C. G. Whitney
Cost-Effectiveness of Vaccination against Invasive Pneumococcal Disease among People 50 through 64 Years of Age: Role of Comorbid Conditions and Race
Ann Intern Med, June 17, 2003; 138(12): 960 - 968.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. Gonzales
A 65-Year-Old Woman With Acute Cough Illness and an Important Engagement
JAMA, May 28, 2003; 289(20): 2701 - 2708.
[Full Text] [PDF]

Home page
 NEJMHome page
L. A. Jackson, K. M. Neuzil, O. Yu, P. Benson, W. E. Barlow, A. L. Adams, C. A. Hanson, L. D. Mahoney, D. K. Shay, W. W. Thompson, et al.
Effectiveness of Pneumococcal Polysaccharide Vaccine in Older Adults
N. Engl. J. Med., May 1, 2003; 348(18): 1747 - 1755.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. E. Singer, I. Harding, M. R. Jacobs, and D. H. Jaffe
Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model
J. Antimicrob. Chemother., May 1, 2003; 51(5): 1269 - 1282.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
A. S. Artz, W. B. Ershler, and D. L. Longo
Pneumococcal Vaccination and Revaccination of Older Adults
Clin. Microbiol. Rev., April 1, 2003; 16(2): 308 - 318.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. Van Kerkhoven, W. E. Peetermans, L. Verbist, and J. Verhaegen
Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral {beta}-lactams
J. Antimicrob. Chemother., March 1, 2003; 51(3): 691 - 696.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. P. Muller, D. E. Low, K. A. Green, A. E. Simor, M. Loeb, D. Gregson, A. McGeer, and and the Ontario Group A Streptococcal Study
Clinical and Epidemiologic Features of Group A Streptococcal Pneumonia in Ontario, Canada
Arch Intern Med, February 24, 2003; 163(4): 467 - 472.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
A.J. CANT, S.B. GORDON, R.C. READ, C.A. HART, and C. WINSTANLEY
Respiratory infections: Proceedings of the Eighth Liverpool Tropical School Bayer Symposium of Microbial Disease held on 3 February 2001
J. Med. Microbiol., November 1, 2002; 51(11): 903 - 914.
[Full Text] [PDF]

Home page
 Med Decis MakingHome page
F. Ahmed, E. E. Elbasha, B. L. Thompson, J. R. Harris, and V.-P. Sneller
Cost-Benefit Analysis of a New HEDIS Performance Measure for Pneumococcal Vaccination
Med Decis Making, October 1, 2002; 22(5_suppl): S58 - S66.
[Abstract] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. Croisier, P. Chavanet, C. Lequeu, A. Ahanou, A. Nierlich, C. Neuwirth, L. Piroth, M. Duong, M. Buisson, and H. Portier
Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones
J. Antimicrob. Chemother., September 1, 2002; 50(3): 349 - 360.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
K.P. Klugman
Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections
Eur. Respir. J., July 1, 2002; 20(36_suppl): 3S - 8s.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
T. Q. Tan, E. O. Mason Jr, E. R. Wald, W. J. Barson, G. E. Schutze, J. S. Bradley, L. B. Givner, R. Yogev, K. S. Kim, and S. L. Kaplan
Clinical Characteristics of Children With Complicated Pneumonia Caused by Streptococcus pneumoniae
Pediatrics, July 1, 2002; 110(1): 1 - 6.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Woodhead
Community-acquired pneumonia in Europe: causative pathogens and resistance patterns
Eur. Respir. J., July 1, 2002; 20(36_suppl): 20S - 27s.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Ortqvist
Treatment of community-acquired lower respiratory tract infections in adults
Eur. Respir. J., July 1, 2002; 20(36_suppl): 40S - 53s.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
W. Bishai
The in vivo-in vitro paradox in pneumococcal respiratory tract infections
J. Antimicrob. Chemother., March 1, 2002; 49(3): 433 - 436.
[Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
Y.-W. Tang, H. Li, J. P. Griffin, D. W. Haas, and E. M. C. D'Agata
Rapidly Increasing Prevalence of Penicillin-Resistant Streptococcuspneumoniae in Middle Tennessee: a 10-Year Clinical and Molecular Analysis
J. Clin. Microbiol., February 1, 2002; 40(2): 395 - 399.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
D. F. Sahm, C. Thornsberry, D. C. Mayfield, M. E. Jones, and J. A. Karlowsky
In Vitro Activities of Broad-Spectrum Cephalosporins against Nonmeningeal Isolates of Streptococcus pneumoniae: MIC Interpretation Using NCCLS M100-S12 Recommendations
J. Clin. Microbiol., February 1, 2002; 40(2): 669 - 674.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. Ball, F. Baquero, O. Cars, T. File, J. Garau, K. Klugman, D. E. Low, E. Rubinstein, R. Wise, and T. Consensus Group on Resistance and Prescribing in R
Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence
J. Antimicrob. Chemother., January 1, 2002; 49(1): 31 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
J. F. Perz, A. S. Craig, D. M. Jorgensen, S. Hall, and W. Schaffner
Evaluation of Innovative Surveillance for Drug-resistant Streptococcus pneumoniae
Am. J. Epidemiol., December 1, 2001; 154(11): 1000 - 1005.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. M. Musher, J. G. Bartlett, and G. V. Doern
A Fresh Look at the Definition of Susceptibility of Streptococcus pneumoniae to {beta}-Lactam Antibiotics
Arch Intern Med, November 26, 2001; 161(21): 2538 - 2544.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
G. L. Mandell
Update in Infectious Diseases
Ann Intern Med, November 20, 2001; 135(10): 897 - 905.
[Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
R. Mangione-Smith, E. A. McGlynn, M. N. Elliott, L. McDonald, C. E. Franz, and R. L. Kravitz
Parent Expectations for Antibiotics, Physician-Parent Communication, and Satisfaction
Arch Pediatr Adolesc Med, July 1, 2001; 155(7): 800 - 806.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. S. Niederman, L. A. Mandell, A. Anzueto, J. B. Bass, W. A. Broughton, G. D. Campbell, N. Dean, T. File, M. J. Fine, P. A. Gross, et al.
Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention
Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1730 - 1754.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Wilson
Bacteria, antibiotics and COPD
Eur. Respir. J., May 1, 2001; 17(5): 995 - 1007.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
L. P. Jetté, G. Delage, L. Ringuette, R. Allard, P. De Wals, F. Lamothe, V. Loo, and the Pneumococcus Study Group
Surveillance of Invasive Streptococcus pneumoniae Infection in the Province of Quebec, Canada, from 1996 to 1998: Serotype Distribution, Antimicrobial Susceptibility, and Clinical Characteristics
J. Clin. Microbiol., February 1, 2001; 39(2): 733 - 737.
[Abstract] [Full Text]

Home page
 NEJMHome page
C. G. Whitney, M. M. Farley, J. Hadler, L. H. Harrison, C. Lexau, A. Reingold, L. Lefkowitz, P. R. Cieslak, M. Cetron, E. R. Zell, et al.
Increasing Prevalence of Multidrug-Resistant Streptococcus pneumoniae in the United States
N. Engl. J. Med., December 28, 2000; 343(26): 1917 - 1924.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. L. Metersky, J. P. Tate, M. J. Fine, M. K. Petrillo, and T. P. Meehan
Temporal Trends in Outcomes of Older Patients With Pneumonia
Arch Intern Med, December 11, 2000; 160(22): 3385 - 3391.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
S. J. Schrag, B. Beall, and S. F. Dowell
Limiting the Spread of Resistant Pneumococci: Biological and Epidemiologic Evidence for the Effectiveness of Alternative Interventions
Clin. Microbiol. Rev., October 1, 2000; 13(4): 588 - 601.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
J. H. Jorgensen, A. L. Barry, M. M. Traczewski, D. F. Sahm, M. L. McElmeel, and S. A. Crawford
Rapid Automated Antimicrobial Susceptibility Testing of Streptococcus pneumoniae by Use of the bioMerieux VITEK 2
J. Clin. Microbiol., August 1, 2000; 38(8): 2814 - 2818.
[Abstract] [Full Text]

Home page
 Arch Intern MedHome page
J. D. Heffelfinger, S. F. Dowell, J. H. Jorgensen, K. P. Klugman, L. R. Mabry, D. M. Musher, J. F. Plouffe, A. Rakowsky, A. Schuchat, C. G. Whitney, et al.
Management of Community-Acquired Pneumonia in the Era of Pneumococcal Resistance: A Report From the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
Arch Intern Med, May 22, 2000; 160(10): 1399 - 1408.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Public Health Association